Switching from posaconazole suspension to tablets increases serum drug levels in leukemia patients without clinically relevant hepatotoxicity.

Abstract

We evaluated posaconazole serum concentrations and hepatotoxicity in 12 leukemia patients who transitioned from posaconazole suspension to tablets. Patients who switched to tablets had significantly increased posaconazole concentrations (median: suspension, 748 ng/ml; tablet, 1,910 ng/ml; P < 0.01) without clinically relevant hepatotoxicity.

• Authors: Dong Sik Jung, Frank P Tverdek, Dimitrios P Kontoyiannis
• Journal: Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 58 Issue 11 Pg. 6993-5 (Nov 2014) ISSN: 1098-6596 [Electronic] United States
• PMID: 25199774 (Publication Type: Comparative Study, Journal Article)
• Copyright: Copyright © 2014, American Society for Microbiology. All Rights Reserved.

Chemical References

• Antifungal Agents
• Suspensions
• Tablets
• Triazoles
• posaconazole

Topics

• Administration, Oral
• Adult
• Aged
• Antifungal Agents (adverse effects, pharmacokinetics, therapeutic use)
• Female
• Food-Drug Interactions
• Gastrointestinal Absorption
• Humans
• Leukemia (microbiology)
• Liver (pathology)
• Male
• Middle Aged
• Mycoses (complications, drug therapy, prevention & control)
• Suspensions (adverse effects)
• Tablets (adverse effects)
• Triazoles (adverse effects, pharmacokinetics, therapeutic use)